Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$4.18 +5.6%	$3.86	$1.78 ▼ $10.00	$269.95M	0.58	829,105 shs	541,479 shs
MDCX Medicus Pharma	$3.31 +10.7%	$4.00	$1.80 ▼ $8.94	$40.58M	N/A	323,318 shs	2.06 million shs
NVCT Nuvectis Pharma	$8.08 +6.6%	$8.76	$4.44 ▼ $11.80	$158.37M	-0.25	133,221 shs	62,573 shs
YMAB Y-mAbs Therapeutics	$4.44 +5.5%	$4.48	$3.55 ▼ $16.11	$190.65M	0.51	295,345 shs	167,823 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	+5.56%	+5.03%	+3.47%	+45.64%	+130.94%
MDCX Medicus Pharma	+10.70%	+2.80%	+14.93%	-1.19%	+330,999,900.00%
NVCT Nuvectis Pharma	+6.60%	+7.45%	-8.70%	-5.16%	+28.66%
YMAB Y-mAbs Therapeutics	+5.46%	+4.23%	-12.60%	+2.07%	-60.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVS Corvus Pharmaceuticals	2.4559 of 5 stars	3.5	1.0	1.6	3.3	0.6
MDCX Medicus Pharma	2.5368 of 5 stars	3.8	0.0	3.2	1.7	0.0
NVCT Nuvectis Pharma	3.1187 of 5 stars	3.5	0.0	3.2	5.0	0.6
YMAB Y-mAbs Therapeutics	3.2789 of 5 stars	4.4	1.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	258.85% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	609.97% Upside
NVCT Nuvectis Pharma	3.00	Buy	$17.00	110.40% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	251.35% Upside

Current Analyst Ratings Breakdown

Latest MDCX, NVCT, YMAB, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.50 per share	N/A
YMAB Y-mAbs Therapeutics	$88.66M	2.27	N/A	N/A	$2.05 per share	2.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$62.29M	-$0.98	N/A	N/A	N/A	N/A	-24.04%	-13.90%	8/5/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.16	N/A	N/A	N/A	N/A	-380.03%	-224.22%	7/10/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.13	N/A	N/A	N/A	N/A	-148.83%	-95.60%	8/5/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.64	N/A	N/A	N/A	-31.84%	-30.59%	-22.70%	8/11/2025 (Estimated)

Latest MDCX, NVCT, YMAB, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	NVCT Nuvectis Pharma	-$0.25	N/A	N/A	N/A	N/A	N/A
7/10/2025	N/A	MDCX Medicus Pharma	-$0.39	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/6/2025	Q1 2025	NVCT Nuvectis Pharma	-$0.30	-$0.27	+$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	4.90	4.90
MDCX Medicus Pharma	N/A	1.53	1.53
NVCT Nuvectis Pharma	N/A	3.28	3.28
YMAB Y-mAbs Therapeutics	N/A	4.77	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
MDCX Medicus Pharma	N/A
NVCT Nuvectis Pharma	96.77%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	28.50%
MDCX Medicus Pharma	11.20%
NVCT Nuvectis Pharma	30.52%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	48.74 million	Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
NVCT Nuvectis Pharma	8	20.89 million	14.52 million	Not Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	36.36 million	Optionable

MDCX, NVCT, YMAB, and CRVS Headlines

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 4, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by Analysts

July 4, 2025 | marketbeat.com

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Y mAbs Therapeutics News (YMAB) - Investing.com

June 26, 2025 | investing.com

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

June 11, 2025 | finance.yahoo.com

Wesbanco Bank Inc. Acquires Shares of 55,000 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on YMAB FY2026 Earnings

June 10, 2025 | marketbeat.com

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28, 2025 | globenewswire.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26, 2025 | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26, 2025 | quiverquant.comQ

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26, 2025 | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13, 2025 | globenewswire.com

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | globenewswire.com

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 7, 2025 | globenewswire.com

Why Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%

May 6, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, NVCT, YMAB, and CRVS Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$4.18 +0.22 (+5.56%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$4.14 -0.04 (-0.93%)

As of 08:00 AM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Medicus Pharma NASDAQ:MDCX

$3.31 +0.32 (+10.70%)

As of 07/9/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Nuvectis Pharma NASDAQ:NVCT

$8.08 +0.50 (+6.60%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$7.90 -0.19 (-2.29%)

As of 08:00 AM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.44 +0.23 (+5.46%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$4.59 +0.15 (+3.47%)

As of 05:01 AM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time